FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology. Disclosed virus-like particle (VLP) for use in producing an immunogenic composition for protection against human cytomegalovirus-related disease, involving: first polypeptide, which is a mouse leukemia virus (MLV) gag polypeptide, the amino acid sequence of which exhibits at least 85 % identity with a self-assembling portion of the original MLV gag protein having the amino acid sequence SEQ ID NO: 1; and a second polypeptide comprising a human cytomegalovirus (HCML) glycoprotein B (gB) protein having a transmembrane domain which is not naturally detectable in gB; wherein said second polypeptide has the amino acid sequence SEQ ID NO: 10. Disclosed is a pharmaceutical composition for protection against human cytomegalovirus disease containing a therapeutically effective amount of the described VLP and a pharmaceutically acceptable excipient.
EFFECT: invention extends the range of cytomegalovirus control agents.
5 cl, 14 dwg, 4 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS FOR DETECTION OF ANTI-CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES | 2013 |
|
RU2660712C2 |
| VIRAL PARTICLE RELEASED AFTER INFECTION OF HUMAN CYTOMEGALOVIR (HCMV) OF MAMMALS CELLS, CONTAINING FUSION PROTEIN, AND ITS APPLICATION | 2011 |
|
RU2623172C2 |
| CONDITIONALLY REPLICATING CYTOMEGALOVIRUS AS VACCINE AGAINST CMV | 2012 |
|
RU2611198C2 |
| MICROPARTICLES FOR DELIVERY OF HETEROLOGOUS NUCLEIC ACIDS | 2001 |
|
RU2295954C2 |
| CONDITIONALLY REPLICATING CYTOMEGALOVIRUS AS VACCINE AGAINST CMV | 2012 |
|
RU2670012C1 |
| IMMUNOGENS FOR VACCINATION AGAINST HIV | 2013 |
|
RU2648791C2 |
| INTRACELLULAR DELIVERY OF BIOMOLECULES FOR IMMUNE RESPONSE MODULATION | 2019 |
|
RU2819143C2 |
| SIMIAN ADENOVIRUS NUCLEIC ACID- AND AMINO ACID-SEQUENCES, VECTORS CONTAINING SAME, AND USE THEREOF | 2010 |
|
RU2604815C2 |
| ANTIGEN DELIVERY PLATFORMS | 2011 |
|
RU2597974C2 |
| COMPOSITION CONTAINING HCMV PARTICLES | 2008 |
|
RU2505314C2 |
